MyAmego Product Launch

Nanoscience Inc
06 May 2008

Embargoed Release: 07:00hrs Tuesday 6 May 2008





                                Nanoscience Inc.

                         ('Nanoscience' or the 'Group')


                   Award winning product launch of MyAmegoTM


Nanoscience, the specialist niche investor in emerging technologies with strong
commercial propositions for the healthcare and electronic sectors, is pleased to
announce that Sentinel Healthcare Solutions Limited ('Sentinel'), where the
Group is the largest shareholder with a fifty per cent interest, secured the
2008 Best New Technology prize for its newly launched MyAmegoTM product on the
last day of the Naidex Exhibition at the Birmingham NEC.


MyAmegoTM is a ground-breaking, patent-pending, cost effective assistive
telecare technology system. It enables care home operators specialising in the
care of people with dementia and other disabilities to deliver a better quality
of care through rigorous risk management procedures and also to construct
personalised detailed assessments which directly relate to the individual.


The privacy of the personal care and monitoring profile is decided by and
managed with the individual and the independence of the person is protected at
all times due to the personalistion of the individuals care plan which further
allows carers and family to have quality, detailed and direct feedback on all
aspects to the persons care. Using Sentinel's Sentinel:Monitor platform,
dementia residents are monitored using their own electronic device, such as a
bracelet or necklace, and the data is captured via wireless monitors placed
around the care home in a mesh network. The service intelligently analyses the
user's environment in relation to the user's needs and automatically alerts
carers for assistance when needed in addition to facilitating the adjustment of
care plans through analysis reports of the user's activities.


MyAmegoTM has successfully completed trials covering a number of conditions and
both private care homes and local authorities across the UK have actively
engaged in commercial discussions. The market size for registered dementia
sufferers in the UK alone exceeds 750,000, with similar ratios to population in
all developed countries.


Sentinel is pleased to report that commercial interest regarding MyAmegoTM at
Naidex, which is UK's largest event for homecare, disability and rehabilitation,
was substantial and the company is vigorously pursuing domestic customer
contacts. Overseas interest from Spain, France, the Netherlands, South Africa,
India and the APAC (Asia and Pacific) region was also on record by the end of
the event.


Sentinel has signed an initial distributor to focus on the local UK health
authorities and is in final negotiations with a further healthcare distributor
who, after purchasing a licence to market and sell MyAmegoTM, will target the
private sector registered care homes.


The Company will continue to explore further agency arrangements across the UK
and overseas as it builds up its presence during 2008.


In total there are more than 28,000 care homes in the UK


Neil Bryant, general manager of Sentinel, commented


'Naidex was the start of transforming how people in care homes are treated and
as the pressure to comply with the Mental Capacity Act and the 'telecare'
requirements laid down by the UK Government, we are positioned to support all
care homes through this cheap and easily delivered solution.'


Guy Spelman, chief executive officer of Nanoscience, commented:


 'We are greatly encouraged by the level of interest Sentinel has received for
MyAmegoTM and we believe the product and services it provides uniquely addresses
the requirements of care providers, people suffering from dementia and not
forgetting their relatives, both from a legal, legislative and quality of care
standpoint.


The Board is confident that the proven abilities of MyAmego's application can
successfully enter the UK care home market, which is worth over #10 billion
annually, in addition to the ever-growing international care home market. We
anticipate the ease of use and cost effective abilities of MyAmegoTM will also
offer numerous opportunities in other geographies and sectors in the future and
we look forward to benefiting from the immense value that we expect our
investment in Sentinel to achieve.'


                                     -Ends-


Further Information:

Guy Spelman    Nanoscience Inc.   07767 338 967
Vikki Krause   Hansard Group      020 7245 1100




                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

NRADGGGKLKMGRZM